EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment‐Based Drug Discovery

Henri Chédotal iD, Katrine Povlsen, Dilip Narayanan, Charlotte H Gotfredsen, Michael Gajhede, Anders Bach iD, Mads H Clausen iD

ChemMedChem · 2026-07-14 · 21 (13)

DOI: 10.1002/cmdc.70365 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-07-03. Written by Henri Chédotal and 6 co-authors. Institution: Department of Chemistry, Technical University of Denmark, Kgs. Lyngby, Denmark. Major MEDLINE topics: Receptors, Tumor Necrosis Factor, Type I, Drug Discovery, Small Molecule Libraries. 48 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Danmarks Frie Forskningsfond, Villum Fonden, Novo Nordisk Fonden.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Tumor necrosis factor receptor 1 (TNFR1) plays a major role in immunoregulation. It is involved in inflammatory and autoimmune diseases like rheumatoid arthritis, psoriasis, Alzheimer’s disease, and multiple sclerosis. However, few small‐molecule inhibitors of TNFR1 have been reported, even though they constitute a good alternative to already existing antibody therapies targeting the TNF pathway. Here, we report the discovery of a new class of molecules for the extracellular domain of TNFR1 using a fragment‐based approach through primary screening by NMR spectroscopy, followed by orthogonal validation by surface plasmon resonance (SPR) and X‐ray crystallography. Guided by these results, we have synthesized 46 analogs with micromolar potency showing up to ∼10‐fold improved affinity toward TNFR1 compared to the fragment hits. These results can provide a structural basis for the discovery of novel TNFR1 inhibitors in the future.

Subjects

MeSH terms (MEDLINE)

Receptors, Tumor Necrosis Factor, Type IDrug DiscoverySmall Molecule LibrariesLigandsHumansCrystallography, X-RaySurface Plasmon ResonanceStructure-Activity RelationshipProtein DomainsMolecular StructureModels, MolecularDose-Response Relationship, Drug

Author keywords

NMRSPRTNFR1fragment‐based screeningprotein crystallography

Substances

Receptors, Tumor Necrosis Factor, Type ILigandsSmall Molecule Libraries

Authors and institutions

  • Department of Chemistry, Technical University of Denmark, Kgs. Lyngby, Denmark.
  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID profiles: Henri Chédotal, Anders Bach, Mads H Clausen

Funding

  • Danmarks Frie Forskningsfond
  • Villum Fonden
  • Novo Nordisk Fonden
  • Carlsbergfondet
  • Vetenskapsrådet
  • VINNOVA
  • Svenska Forskningsrådet Formas

Cite

APA

Chédotal, H., Povlsen, K., Narayanan, D., Gotfredsen, C. H., Gajhede, M., Bach, A., & Clausen, M. H. (2026). Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment‐Based Drug Discovery. ChemMedChem, 21(13). https://doi.org/10.1002/cmdc.70365

Vancouver

Chédotal H, Povlsen K, Narayanan D, Gotfredsen CH, Gajhede M, Bach A, et al. Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment‐Based Drug Discovery. ChemMedChem. 2026;21(13). doi:10.1002/cmdc.70365

BibTeX
@article{Chdotal2026,
  author = {Chédotal, Henri and Povlsen, Katrine and Narayanan, Dilip and Gotfredsen, Charlotte H and Gajhede, Michael and Bach, Anders and Clausen, Mads H},
  title = {Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment‐Based Drug Discovery},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {13},
  doi = {10.1002/cmdc.70365}
}
Start for free →